- Home
- NPWR vs CRDF Comparison
NPWR vs CRDF Comparison
Compare NPWR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- CRDF
- Stock Information
- Founded
- NPWR 2010
- CRDF 1999
- Country
- NPWR United States
- CRDF United States
- Employees
- NPWR N/A
- CRDF N/A
- Industry
- NPWR Industrial Machinery/Components
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPWR Energy
- CRDF Health Care
- Exchange
- NPWR Nasdaq
- CRDF Nasdaq
- Market Cap
- NPWR 148.7M
- CRDF 169.6M
- IPO Year
- NPWR N/A
- CRDF N/A
- Fundamental
- Price
- NPWR $2.13
- CRDF $3.35
- Analyst Decision
- NPWR Buy
- CRDF Strong Buy
- Analyst Count
- NPWR 2
- CRDF 4
- Target Price
- NPWR $4.00
- CRDF $12.25
- AVG Volume (30 Days)
- NPWR 1.3M
- CRDF 839.8K
- Earning Date
- NPWR 05-12-2025
- CRDF 05-08-2025
- Dividend Yield
- NPWR N/A
- CRDF N/A
- EPS Growth
- NPWR N/A
- CRDF N/A
- EPS
- NPWR N/A
- CRDF N/A
- Revenue
- NPWR $250,000.00
- CRDF $587,000.00
- Revenue This Year
- NPWR $308.00
- CRDF N/A
- Revenue Next Year
- NPWR $1,811.08
- CRDF N/A
- P/E Ratio
- NPWR N/A
- CRDF N/A
- Revenue Growth
- NPWR 100.00
- CRDF N/A
- 52 Week Low
- NPWR $1.48
- CRDF $2.01
- 52 Week High
- NPWR $14.28
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NPWR 55.27
- CRDF 63.72
- Support Level
- NPWR $1.48
- CRDF $2.81
- Resistance Level
- NPWR $1.75
- CRDF $3.43
- Average True Range (ATR)
- NPWR 0.24
- CRDF 0.19
- MACD
- NPWR 0.10
- CRDF 0.08
- Stochastic Oscillator
- NPWR 56.52
- CRDF 85.54
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.